-+ 0.00%
-+ 0.00%
-+ 0.00%

Bausch Health signs letter of intent with pan-Canadian Pharmaceutical Alliance for public coverage of OKEDI schizophrenia drug

PUBT·06/09/2026 14:03:35
Listen to the news
Bausch Health signs letter of intent with pan-Canadian Pharmaceutical Alliance for public coverage of OKEDI schizophrenia drug
  • Bausch Health’s Canadian unit signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for public drug plan coverage of OKEDI.
  • The deal covers monthly extended-release injectable risperidone 75 mg and 100 mg for adult schizophrenia.
  • The letter is a step toward listing agreements with federal, provincial, territorial public plans, including Indigenous and veterans’ programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.